The effect of desolvation on the binding of inhibitors to HIV-1 protease and cyclin-dependent kinases: Causes of resistance

被引:8
|
作者
Fong, Clifford W. [1 ]
机构
[1] Eigenenergy, Adelaide, SA, Australia
关键词
QSAR model; HIV-1 protease inhibitors; CDK inhibitors; Kinase binding; Quantum mechanics; RECOGNITION; ENTHALPY; ENERGY; MODELS;
D O I
10.1016/j.bmcl.2016.05.080
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Studies of the cyclin-dependent kinase inhibitors and HIV-1 protease inhibitors have confirmed that ligand-protein binding is dependent on desolvation effects. It has been found that a four parameter linear model incorporating desolvation energy, lipophilicity, dipole moment and molecular volume of the ligands is a good model to describe the binding between ligands and kinases or proteases. The resistance shown by MDR proteases to the anti-viral drugs is multi-faceted involving varying changes in desolvation, lipophilicity and dipole moment interaction compared to the non-resistant protease. Desolvation has been shown to be the dominant factor influencing the effect of inhibitors against the cyclin-dependent kinases, but lipophilicity and dipole moment are also significant factors. The model can differentiate between the inhibitory activity of CDK2/cycE, CDK1/cycB and CDK4/cycD enzymes. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3705 / 3713
页数:9
相关论文
共 50 条
  • [41] Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development
    Chellappan, SP
    Giordano, A
    Fisher, PB
    CYCLIN DEPENDENT KINASE (CDK) INHIBITORS, 1998, 227 : 57 - 103
  • [42] Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics
    Fischer, PM
    Lane, DP
    CURRENT MEDICINAL CHEMISTRY, 2000, 7 (12) : 1213 - 1245
  • [43] Synthesis and SAR of pyrazolopyridine inhibitors of cyclin-dependent kinases.
    Misra, RN
    Rawlins, DB
    Bursuker, I
    Kellar, KA
    Kimball, SD
    Mulheron, JG
    Sack, JS
    Shan, W
    Xiao, HY
    Webster, KR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U9 - U9
  • [44] p16 family inhibitors of cyclin-dependent kinases
    Li, Y
    Jenkins, CW
    Nichols, MA
    Wu, XY
    Guan, KL
    Xiong, Y
    CANCER GENES: FUNCTIONAL ASPECTS, 1996, 7 : 57 - 82
  • [45] 8-Azapurines as new inhibitors of cyclin-dependent kinases
    Havlicek, L
    Fuksova, K
    Krystof, V
    Orsag, M
    Vojtesek, B
    Strnad, M
    BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (18) : 5399 - 5407
  • [46] Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1
    Oumata, Nassima
    Bettayeb, Karima
    Ferandin, Yoan
    Demange, Luc
    Lopez-Giral, Angela
    Goddard, Marie-Lorene
    Myrianthopoulos, Vassilios
    Mikros, Emmanuel
    Flajolet, Marc
    Greengard, Paul
    Meijer, Laurent
    Galons, Herve
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (17) : 5229 - 5242
  • [47] Computational Prediction of HIV-1 Resistance to Protease Inhibitors
    Hosseini, Ali
    Alibes, Andreu
    Noguera-Julian, Marc
    Gil, Victor
    Paredes, Roger
    Soliva, Robert
    Orozco, Modesto
    Guallar, Victor
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2016, 56 (05) : 915 - 923
  • [48] Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
    Wang, Bin
    Li, Rui
    Wu, Shuai
    Liu, Xin
    Ren, Jianlin
    Li, Jing
    Bi, Kaixin
    Wang, Yanhong
    Jia, Hongyan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] HIV-1 resistance to binding/fusion inhibitors
    Esté, JA
    Clotet, B
    ANTIVIRAL RESEARCH, 2004, 62 (02) : A31 - A32